Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL85354 | 0.78 | GOT1 (0.35) | GOT1 | |
| SCHEMBL21101452 | 0.77 | KIF11 (0.32) | KIF11 | |
| SCHEMBL179262 | 0.73 | GOT1 (0.38) | KIF11GOT1 | |
| SCHEMBL11125404 | 0.72 | GOT1 (0.31) | GOT1 | |
| Hydrochloric Acid SCHEMBL31617638 | 0.71 | GOT1 (0.37) | KIF11GOT1 | |
| SCHEMBL19872223 | 0.70 | GOT1 (0.35) | GOT1 | |
| SCHEMBL29083684 | 0.70 | GOT1 (0.35) | GOT1 | |
| SCHEMBL20128939 | 0.70 | GOT1 (0.35) | GOT1 | |
| SCHEMBL10435695 | 0.69 | ALDH1A1 (0.41) | GOT1 | |
| SCHEMBL85739 | 0.68 | KIF11 (0.46) | KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200385391-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2020-12-10 | — | — | US | disclosed |
| US-10702528-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20190216808-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARM INC (US) | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10702528-B2 | Hepatitis B antiviral agents | HAVCR2, SLC10A1, HDGF | KIF11 3984/4885GOT1 54/4885 |
| US-20200385391-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, SLC10A1, HDGF | KIF11 3074/4885GOT1 61/4885 |
| US-20190216808-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, SLC10A1, HDGF | KIF11 3984/4885GOT1 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.